VivoSeq
Infectious Disease

Herpes Simplex Virus

0

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

Herpes Simplex Virus is an early-stage landscape with 0 programs across 5 companies. The most active players are GSK, Heidelberg ImmunoTherapeutics GmbH, OrienGene Biotechnology Ltd..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

PreclinicalH

Heidelberg ImmunoTherapeutics GmbH

0 programs

PreclinicalO

OrienGene Biotechnology Ltd.

0 programs

PreclinicalC

Changchun BCHT Biotechnology Co.

0 programs

PreclinicalS

Shaman Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

29

clinical trials

Completed21 · 72%
Unknown status3 · 10%
Terminated2 · 7%
Enrolling by invitation1 · 3%
Available1 · 3%
Not yet recruiting1 · 3%

Clinical Trials

Trial Activity

29 trials

Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy
Not yet recruiting·EEG 427·Phase 1/2·NCT07227285·16 enrolled
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
Enrolling by invitation·CChangchun BCHT Biotechnology Co.·Phase 1·NCT07330440·144 enrolled
The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment
Completed·AAstra USA·Phase 1·NCT00002144·12 enrolled
Valaciclovir to Prevent Transmission of Herpes Simplex Virus
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00001649·180 enrolled
Phase III Randomized, Placebo-Controlled Study of Acyclovir Oral Suspension for Neonatal Herpes Simplex Virus Infection Limited to the Skin, Eyes, and Mouth
Completed·NNational Center for Research Resources (NCRR)·Phase 3·NCT00004757
The Effect of Acyclovir Treatment of the Herpes Simplex Virus (HSV) Infection on HIV Levels in the Blood
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001115·75 enrolled
A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer
Completed·OOrienGene Biotechnology Ltd.·Phase 1·NCT01935453·18 enrolled
Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix
Completed·UUniversity of Toronto·N/A·NCT00946556·30 enrolled
Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00031447·29 enrolled
Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV
Completed·UUniversity of Washington·Phase 4·NCT00527618·28 enrolled
Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Abreva in the Suppression of Herpes Simplex Virus Eruptions
Completed·UUniversity of Utah·Phase 2·NCT06558838·40 enrolled
EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions
Completed·UUniversity of Utah·Phase 2·NCT04893577·10 enrolled
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection
Completed·HHeidelberg ImmunoTherapeutics GmbH·Phase 2·NCT04165122·122 enrolled
SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir
Completed·SShaman Pharmaceuticals·N/A·NCT00002310
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Completed·GSK logoGSK·Phase 4·NCT00116844·73 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)